NewsHaleos Labs Limited Issues Postal Ballot Notice for Director Reappointment and Material Related Party TransactionsHaleos Labs Limited Issues Postal Ballot Notice for Director Reappointment and Material Related Party Transactions
Haleos Labs Limited has issued a postal ballot notice dated 29th May, 2026, seeking shareholder approval via remote e-voting for four resolutions, including the reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for 5 (five) years from 2nd September, 2026, and approval of aggregate managerial remuneration for Executive Directors up to a maximum of ₹3,54,00,000 per annum plus perquisites. The company, with an annual consolidated turnover of ₹333.79 Crores for 2025-26, is also seeking approval for material related party transactions with Mahi Drugs Private Limited (up to ₹85.10 Crores), Purogene Labs Private Limited (up to ₹50.60 Crores), and ChemWerth Inc, USA (up to ₹55.00 Crores) for the year 2026-27. The e-voting window is open from 30th July, 2026 to 28th August, 2026, with results to be declared on 31st August, 2026.
*this image is generated using AI for illustrative purposes only.
Haleos Labs Limited (formerly known as SMS Lifesciences India Limited) has issued a postal ballot notice dated 29th May, 2026, inviting shareholders to vote on four key resolutions via remote e-voting. The notice has been issued pursuant to Section 108 and 110 of the Companies Act, 2013, read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has engaged Central Depository Services (India) Limited (CDSL) as the authorised e-voting agency for facilitating the process.
Voting Schedule and Key Dates
Shareholders are requested to cast their votes electronically within the stipulated window. The key dates for this postal ballot are as follows:
| Parameter: | Details |
|---|---|
| Voting Start Date: | Thursday, 30th July, 2026 at 09.00 am (IST) |
| Voting End Date: | Friday, 28th August, 2026 at 05.00 pm (IST) |
| Cut-off Date: | Friday, 24th July, 2026 |
| Result Declaration: | Monday, 31st August, 2026 |
| Scrutinizer: | Mr. C. Sudhir Babu (FCS No. 7666), Practicing Company Secretary |
Resolutions, if passed by the requisite majority, shall be deemed to have been passed on Friday, 28th August, 2026, the last date specified for receipt of votes through the e-voting process.
Resolutions Proposed
The following four resolutions are being placed before shareholders for approval:
| Sr. No. | Particulars of Resolution | Type of Resolution |
|---|---|---|
| 1. | Reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for a period of 5 (five) years | Special Resolution |
| 2. | Approval for payment of managerial remuneration to Executive Directors pursuant to Regulation 17(6)(e) of SEBI (LODR) Regulations, 2015 | Special Resolution |
| 3. | Approval of Material Related Party Transactions of the Company for the year 2026-27 | Ordinary Resolution |
| 4. | Approval of Material Related Party Transactions of the Material Subsidiary of the Company for the year 2026-27 | Ordinary Resolution |
Reappointment of Whole-Time Director
Mrs. Sudeepthi Gopineedi (DIN: 09102540) was originally appointed as Whole-Time Director at the 15th Annual General Meeting held on 30th September, 2021, for a period of 5 (five) years effective from 2nd September, 2021. Her current tenure is set to conclude on 1st September, 2026. The Board of Directors, at its meeting held on 29th May, 2026, on the recommendation of the Nomination and Remuneration Committee and Audit Committee, approved her reappointment for a further period of 5 (five) years commencing from 2nd September, 2026, subject to shareholder approval.
Mrs. Sudeepthi Gopineedi is a postgraduate from Birla Institute of Technology and Science (BITS), Pilani, holding a Masters in Chemistry and a Bachelors in Computer Science Engineering. Prior to joining the company, she worked with multinational organisations including Amazon, Oracle, The World Bank, and Blue Cross Blue Shield Association. She joined the company in 2018 as General Manager – Operations and has since led key quality and operational initiatives, including the successful completion of USFDA inspections and several regulatory and customer audits.
Director Profile and Remuneration Details
| Parameter: | Details |
|---|---|
| Name: | Mrs. Sudeepthi Gopineedi |
| DIN: | 09102540 |
| Date of Birth: | 02.03.1987 |
| Nationality: | Indian |
| Date of First Appointment: | 02.09.2021 |
| Shareholding: | 1,99,494 (6.60%) |
| Board Meetings Attended (2025-26): | 4 out of 4 |
| Relationship with Other Directors: | Daughter of Mr. TVVSN Murthy, Managing Director; Sibling of Mr. TV Praveen, Executive Director |
| Directorships in Other Listed Entities: | Nil |
The remuneration drawn by Mrs. Sudeepthi Gopineedi in the last year (FY 2025-26) is detailed below:
| Component: | Amount |
|---|---|
| Salary: | ₹24,00,000 |
| Perks: | ₹2,76,947 |
| Total: | ₹26,76,947 |
| % of Net Profit: | 0.94% |
The proposed monthly remuneration for the reappointment period is in the range of ₹2.50 lakhs to ₹4.00 lakhs, as may be determined from time to time by the Nomination and Remuneration Committee and the Board of Directors.
Managerial Remuneration for Executive Directors
Fresh shareholder approval is being sought for aggregate managerial remuneration payable to Executive Directors, as it may exceed the prescribed limit of 5% (five percent) of the net profits of the Company computed in accordance with Section 198 of the Companies Act, 2013. The previously approved remuneration structure (vide Postal Ballot dated 30th July, 2025) and the proposed maximum remuneration are set out below:
Previously Approved Remuneration:
| Name of Executive Director | Monthly Remuneration (₹) | Annual Remuneration (₹) |
|---|---|---|
| Mr. TVVSN Murthy | 16,50,000 | 1,98,00,000 |
| Mr. TV Praveen | 9,00,000 | 1,08,00,000 |
| Mrs. Sudeepthi Gopineedi | 2,00,000 | 24,00,000 |
| Total | 27,50,000 | 3,30,00,000 |
Plus perquisites
Proposed Maximum Remuneration:
| Name of Executive Director | Maximum Monthly Remuneration (₹) | Maximum Annual Remuneration (₹) |
|---|---|---|
| Mr. TVVSN Murthy | 16,50,000 | 1,98,00,000 |
| Mr. TV Praveen | 9,00,000 | 1,08,00,000 |
| Mrs. Sudeepthi Gopineedi | 4,00,000 | 48,00,000 |
| Total | 29,50,000 | 3,54,00,000 |
Plus perquisites
The resolution further provides that where in any year the company has no profits or profits are inadequate, the overall annual managerial remuneration paid to the Executive Directors shall not exceed ₹5,00,00,000/- (Rupees Five Crores Only).
Material Related Party Transactions for 2026-27
Haleos Labs is engaged in the manufacturing, research, development, and commercialisation of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and bulk drugs. The annual consolidated turnover of the company for the year 2025-26 was ₹333.79 Crores. Based on this, the materiality threshold works out to ₹33.37 Crores (10% of consolidated turnover of ₹333.79 Crores).
Material RPTs of the Company
The following transactions have been proposed as Material Related Party Transactions of the company for the year 2026-27:
[₹ in Crores]
| Name of Related Party | Nature of Transaction | Threshold Limit | Aggregate Proposed Limits |
|---|---|---|---|
| Mahi Drugs Private Limited (Subsidiary) | Sale & Purchase of Goods & Services, rent and business advances | 33.37 | 85.10 |
| Purogene Labs Private Limited (Directors have significant influence) | Sale & Purchase of Goods & Services, rent and business advances | 33.37 | 50.60 |
Transactions during the year 2025-26 with these related parties were as follows:
Mahi Drugs Private Limited (₹ in lakhs):
| Nature of Transaction | Amount (₹ in lakhs) |
|---|---|
| Purchase of Goods | 2,623.61 |
| Sale of Goods | 483.05 |
| Lease Rent Received | 6.37 |
| Issued Corporate Guarantee | 2,000.00 |
| Total | 5,113.03 |
Purogene Labs Private Limited (₹ in lakhs):
| Nature of Transaction | Amount (₹ in lakhs) |
|---|---|
| Purchase of Goods | 382.82 |
| Sale of Goods | 321.61 |
| Purchase of Service | 1,693.42 |
| Lease Rent Received | 4.25 |
| Total | 2,402.10 |
Material RPTs of the Material Subsidiary
The standalone turnover of the subsidiary company (Mahi Drugs Private Limited) for the year 2025-26 was ₹59.02 Crores. The following transaction has been proposed as a Material Related Party Transaction of the material subsidiary for the year 2026-27:
[₹ in Crores]
| Name of Related Party | Nature of Transaction | Threshold Limit | Aggregate Proposed Limits |
|---|---|---|---|
| ChemWerth Inc, USA (Other related party) | Sale & Purchase of Goods & Services, Business advance | 33.37 | 55.00 |
Transactions with ChemWerth Inc during the year 2025-26 amounted to ₹114.12 lakhs in aggregate (Sale of Goods: ₹88.98 lakhs; Sale of Services: ₹25.14 lakhs). All proposed related party transactions are to be undertaken in the ordinary course of business and on an arm's length basis, and shall be reviewed and monitored on a quarterly basis by the Audit Committee.
E-Voting and Contact Details
Shareholders may contact the following for queries or grievances related to this postal ballot:
- Company: Haleos Labs Limited — Phone: 40-6628 8888 / 9861129909 | Email: info@haleoslabs.com / cs@haleoslabs.com
- Registrar & Transfer Agent: Aarthi Consultants Private Limited — Phone: 040-27638777 / 27642217 / 27634445 | Email: info@aarthiconsultants.com
- e-Voting Agency: Central Depository Services (India) Limited — Phone: 022-23058738 and 022-23058542/43 | Email: helpdesk.evoting@cdslindia.com
- Scrutinizer: Mr. C. Sudhir Babu, Practicing Company Secretary — Phone: 7981191458 / 9493676368 | Email: csbassociates27@gmail.com
Historical Stock Returns for Haleos
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.77% | -0.54% | +15.19% | +36.34% | +37.50% | +120.82% |
How might the proposed increase in Mrs. Sudeepthi Gopineedi's remuneration cap impact shareholder sentiment and the company's cost structure in the coming fiscal year?
What strategic implications do the significantly higher aggregate limits for related party transactions with Mahi Drugs and Purogene Labs have for Haleos Labs' operational independence and regulatory compliance?
Given the family-owned nature of the executive leadership, how will the reappointment of Mrs. Gopineedi influence corporate governance perceptions among institutional investors?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
